Home » Nanotherapeutics Begins Patient Enrollment in Phase II Trial of Triapine
Nanotherapeutics Begins Patient Enrollment in Phase II Trial of Triapine
U.S.-based biopharmaceutical company Nanotherapeutics has started enrollment of first patient in a Phase II cervical cancer trial for Triapine, a ribonucleotidereductase inhibitor.
Pharmaceutical Business Review
Pharmaceutical Business Review
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May